Top

Published in:

01-02-2011 | Bone and Soft Tissue Sarcomas

ILP and RT: The Study That Will Never Be

Authors: Sylvie Bonvalot, MD, PhD, Alessandro Gronchi, MD

Published in: Annals of Surgical Oncology | Issue 2/2011

Excerpt

In the report by Deroose et al., the Rotterdam team tries to address the question of the added value of radiotherapy (RT) to isolated limb perfusion (ILP).1 This is an important question that, thanks to the toxicities that the combined treatments may cause, deserves an answer. …

Deroose JP, Burger JWA, van Geel AN, et al. Radiotherapy for soft tissue sarcoma after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann Surg Oncol. 2010. doi: 10.1245/s10434-010-1400-x.

Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756–64.

Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFa and melphalan for non-resectable soft tissue sarcomas of the extremities. Eur J Surg Oncol. 2000;26:669–78.PubMedCrossRef

Bonvalot S, Rimareix F, Causeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol. 2009;16:3350–7.PubMedCrossRef

Hayes AJ, Neuhaus SJ, Clark MA, et al. Isolated limb perfusion with Melphalan and tumor necrosis factor alpha for advanced melanoma and soft tissue sarcoma. Ann Surg Oncol. 2007;14:230–8.PubMedCrossRef

Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14:553–9.PubMedCrossRef

van Ginkel RJ, Thijssens KM, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol. 2007;14:1499–506.PubMedCrossRef

Hohenberger P, et al. Functional outcome after preoperative isolated limb perfusion with rhTNFalpha/melphalan for high-grade extremity sarcoma. Eur J Cancer. 2001;37:S34–5.CrossRef

Grabellus F, Kraft C, Sheu SY, et al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol. 2009;16:676–86.PubMedCrossRef

10.

Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003;98:1483–90.PubMedCrossRef

11.

Gronchi A, Palmerini E, Demetri G, et al. 2009. A phase II clinical trial of neoadjuvant trabectedin in patients with non metastatic advanced myxoid/round cell liposarcoma (MRCL). Eur J Cancer. 7: 589.

12.

Thijssens KM, van Ginkel RJ, Pras E, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol. 2006;13:518–24.PubMedCrossRef

13.

Muret J, Yacoub M, Terrier P, et al. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol. 2008;19:793–800.PubMedCrossRef

14.

Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2007;14:2105–12.PubMedCrossRef

15.

Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007;246:675–81.PubMedCrossRef

16.

Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251:506–11.PubMedCrossRef

17.

Bonvalot S, Dunant A, le Pechoux C, et al. Quality of surgical margins and local recurrence in primary extremity soft tissue sarcoma (STS). J Clin Oncol. 2010;28(15_suppl):10068.

Title: ILP and RT: The Study That Will Never Be
Authors: Sylvie Bonvalot, MD, PhD
Alessandro Gronchi, MD
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1461-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ILP and RT: The Study That Will Never Be

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

Tumor Depth as a Predictor of Lymph Node Metastasis of Supraglottic and Hypopharyngeal Cancers

Pretherapeutic Extraperitoneal Laparoscopic Staging of Bulky or Locally Advanced Cervical Cancer

Invasive IPMN and MCN: Same Organ, Sifferent Outcomes?

Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines

A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma

Resection Margins in Ultrasound-Guided Breast-Conserving Surgery